Drug Profile
BIOD 123
Alternative Names: BIOD-123Latest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator Biodel
- Developer Albireo Pharma
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Diabetes mellitus
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 02 Mar 2023 Albireo Pharma has been acquired by Ipsen
- 18 Dec 2019 No development reported - Phase-II for Type 1 diabetes mellitus in USA (SC)
- 26 Aug 2015 Phase-II development was completed for Type-1 diabetes mellitus in USA